MedPath

Streptococcus pneumoniae type 6b capsular polysaccharide antigen

Generic Name
Streptococcus pneumoniae type 6b capsular polysaccharide antigen
Brand Names
Pneumovax 23, Prevnar 13, Vaxneuvance, Prevenar 13, Prevenar 20 (previously Apexxnar)
Drug Type
Biotech
Unique Ingredient Identifier
57F7254B6Q

Overview

Streptococcus pneumoniae type 6b capsular polysaccharide antigen is a vaccine that contains highly purified capsular polysaccharides from the invasive pneumococcal type 6b of Streptococcus pneumoniae. It is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia.

Indication

No indication information available.

Associated Conditions

  • Pneumococcal Infection

Clinical Trials

FDA Drug Approvals

Approved Product
Manufacturer
NDC Code
Route
Strength
Effective Date
No FDA approvals found for this drug.

HSA Drug Approvals

Approved Product
Manufacturer
Approval Number
Dosage Form
Strength
Approval Date
APEXXNAR SUSPENSION FOR INJECTION IN SINGLE-DOSE PRE-FILLED SYRINGE 0.5ML
SIN16648P
INJECTION, SUSPENSION
4.4 μg/0.5ml
11/30/2022
Prevenar 13 Suspension For Injection
SIN13824P
INJECTION, SUSPENSION
4.4mcg
7/2/2010

NMPA Drug Approvals

Approved Product
Company
Approval Number
Drug Type
Dosage Form
Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product
Registration No.
Company
Licence No.
Strength
Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product
ARTG ID
Sponsor
Registration Type
Status
Registration Date
No TGA approvals found for this drug.

Help Us Improve

Your feedback helps us provide better drug information and insights.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.